Cure8 trial brief
A validated pre-endoscopic model could help estimate UC disease extent before colonoscopy, aiding clinical triage and planning without replacing endoscopy.
Clinicians (gastroenterologists, IBD nurses), researchers in AI/IBD diagnostics, and adult patients interested in noninvasive disease assessment
This is a multicenter, retrospective observational study with development and external validation cohorts. The planned enrollment is 1,500 patients overall, with an external validation cohort of 247 used for the primary outcome (macro AUC one-vs-rest for three-class Montreal extent prediction).
Predictors are pre-endoscopic symptoms, signs, and laboratory tests; the model will not use endoscopic findings as inputs. The study is registered as ACTIVE_NOT_RECRUITING and describes nested cross-validation for model development and independent external validation.
The registry record clarifies this is intended as a decision-support tool and explicitly states it is not a replacement for colonoscopy or histopathology.
This is a registered observational study (ACTIVE_NOT_RECRUITING) describing planned development and external validation; the registry entry does not report study results, so interpretative claims should await full results and peer review.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial tests a new oral drug for moderate-to-severe ulcerative colitis and could expand treatment options if later shown to be safe and effective. It also targets patients who have had inadequate response or...
This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...
This trial tests whether adding an investigational oral agent (LY4268989) to mirikizumab improves remission rates in people with moderately to severely active ulcerative colitis. If successful, it could expand treatment...
